Abstract 4158
Background
Tumor-associated macrophages (TAMs) constitute over 50% of the number of cells in breast malignancies. In mouse models, most TAMs in the breast cancer microenvironment behave as the M2-like phenotype, with protumor characteristics, but the roles of TAMs in human breast cancer are poorly understand. Specific TAMs related molecular mechanisms among different intrinsic molecular subtypes remain unclear. Here, we focused on studying protumor TAM markers among human breast cancer tissues: CD163, CD204, CD206 which commonly used in mouse models. We identify and explore roles of TAMs novel marker: CD204 in intrinsic molecular subtypes of breast cancer.
Methods
Expression of CD204, CD163, CD206 and clinical outcome of CD204 were analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Potential Kyoto Encyclopedia of Genes and Genomes (KEGG) and HALLMARK pathways regulated by CD204 were studied using Gene Set Enrichment Analysis (GSEA). We used CIBERSOT to estimate the immune contextures regulated by CD204 among different subtypes and the correlations of CD204 and immune suppressive molecules were also analyzed.
Results
Compared to CD163, CD206, only CD204 was found upregulated in breast cancer compared to the normal tissue, associated with poor OS, RFS, and DMFS. The expression of CD204 was different between 4 subtypes. CD204 was involved in immune system-related pathways including innate and adaptive immunity among all subtypes. Numerous special pathways were also found influenced by CD204: tumor metabolism-related pathways in luminal A, Hippo and TGF-β signaling pathways in luminal B, cell cycle process in HER-2 amplified, and RIG-I-like receptor signaling pathway in basal-like subtype. Strong correlations between CD204 and immune cells especially for protumor populations were displayed, and most immunosuppressive molecules: HIF1A, FAP, IL10, PDCD1/CD274, CTLA4, HAVCR2, positive correlated with CD204 expression in all subtypes.
Conclusions
CD204 could become an applicable marker of TAMs in human breast cancer. These findings contribute to better understanding and managing of TAMs in different subtypes of breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jinhai Tang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract